Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: A close look at the evidence

Gut

Volumn 53, Issue 1, 2004, Pages 143-148

  Thalheimer, U ^a   Mela, M ^a   Patch, D ^a   Burroughs, A K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NADOLOL; PROPRANOLOL;

ALCOHOL LIVER DISEASE; BLEEDING; BLOOD PRESSURE MONITORING; CLINICAL PRACTICE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LIVER CIRRHOSIS; POPULATION RESEARCH; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRESSURE GRADIENT; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RECURRENT DISEASE; RECURRENT VARICEAL BLEEDING; RELIABILITY; REVIEW; RISK REDUCTION; SECONDARY PREVENTION;

ANTIHYPERTENSIVE AGENTS; DRUG MONITORING; ESOPHAGEAL AND GASTRIC VARICES; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; PORTAL PRESSURE;

EID: 0345830638     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.53.1.143     Document Type: Review

References (50)

1. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54.
2. DeFranchis R, Primignani M. Endoscopic treatment for portal hypertension. Semin Liver Dis 1999;19:439-55.
3. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation fat primary prophylaxis of esophageal bleeding. Hepatology 2000;33:1003-4.
4. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001;345:647-55.
5. Lo G-H, Chen W-C, Chen M-H, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002;123:728-34.
6. Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002;123:1013-19.
7. Bosch J. A la carte or menu fixe: improving pharmacologic therapy of portal hypertension. Hepatology 2002;36:1330-2.
8. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003;38(suppl 1):S54-68.
9. Bosch J, García-Pagán JC. Prevention of variceal bleeding. Lancet 2003;361:952-4.
10. Hicken BL, Sharara AI, Abrams GA, et al. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. Aliment Pharmacol Ther 2003;17:145-53.
11. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
12. Vorobioff J, Groszmann RJ, Pibacea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111:701-9.
13. Bureau C, Péron JM, Alric L, et al. "A la carte" treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology 2002;36:1361-6.
14. Groszmann RJ, Garcia-Tsao G. Endoscopic variceal banding vs. pharmacological therapy for the prevention of recurrent variceal haemorrhage: what makes the difference. Gastroenterology 2002;123:1388-91.
15. Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
16. Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-9.
17. McCormick PA, Patch D, Greenslade L, et al. Clinical vs hemodynamic response to drugs in portal hypertension. J Hepatol 1998;28:1015-19.
18. Sacerdoti D, Merkel C, Gatta A. Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. J Hepatol 1991;12:124-5.
19. Armonis A, Patch D, Burroughs AK. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? Hepatology 1997;25:245-8.
20. Vinel JP, Cassigneul J, Levade M, et al. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepotic gradient. Hepatology 1986;6:116-17.
21. Burroughs AK, Jenkins WJ, Sherlock S, et al. Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med 1983;309:1539-42.
22. Escorsell A, Bañares R, García-Pagán JC, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002;35:385-92.
23. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626-31.
24. Valla D, Jiron MI, Poynard T, et al. Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol 1987;5:144-8.
25. Patch D, Armonis A, Sabin K, et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut 1999;44:264-9.
26. Vlavianos P, Gimson ES, Hayllar K, et al. Prognostic significance of systemic and portal haemodynamic parameters in patients with cirrhosis and previous variceal bleeding. Gut 1990;31:592A.
27. De BK, Sen S, Biswas PK, et al. Propranolol in primary and secondary prophylaxis of variceal bleeding among cirrhotics in India: a hemodynamic evaluation. Am J Gastroenterol 2000;95:2023-8.
28. Escorsell A, Bordas JM, Castañeda B, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000;31:1061-7.
29. Escorsell A, Ferayorni L, Bosch J, et al. The portal pressure response to β-blockade is greater in cirrhotic patients without varices than in those with varices. Gastroenterology 1997;112:2012-16.
30. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902-8.
31. Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;32:930-4.
32. Abraczinskas DR, Ookubo R, Grace ND, et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology 2001;34:1096-102.
33. Keiding S, Vilstrup H. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis. Scand J Gastroenterol 2002;37:960-4.
34. Rector WG. Propranolol for portal hypertension. Evaluation of therapeutic response by direct measurement of portal vein pressure. Arch Intern Med 1985;145:648-50.
35. Viallet A, Joly JG, Marleau D, et al. Comparison of free portal venous pressure and wedged hepatic venous pressure in patients with cirrhosis of the liver. Gastroenterology 1970;59:372-5.
36. Iwao T, Toyonaga A, Ikegami M, et al. Wedged hepatic venous pressure reflects portal venous pressure during vasoactive drug administration in non-alcoholic cirrhosis. Dig Dis Sci 1994;39:2439-44.
37. Perelló A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999;30:1393-7.
38. Boyer TD, Triger DR, Horisawa M, et al. Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology 1977;72:584-9.
39. Groszmann RJ, Glickman M, Blei AT, et al. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology 1979;76:253-8.
40. Lin HC, Tsai YT, Lee FY, et al. Comparison between portal vein pressure and wedged hepatic vein pressure in hepatitis B-related cirrhosis. J Hepatol 1989;9:326-30.
41. Reynolds TB, Ito S, Iwatsuki S. Measurement of portal pressure and its clinical application. Am J Med 1970;49:649-57.
42. Reynolds TB, Geller HM, Kuzma OT, et al. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 1960;263:734-9.
43. Okumura H, Arakami T, Katsuta Y, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
44. García-Pagán J, Salmeron J, Feu F, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. Hepatology 1994;19:1095-9.
45. Sugano S, Kawafune T, Okajima T, et al. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 1998;43:893-7.
46. Nevens F, Lijnen P, VanBilloen H, et al. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. Hepatology 1996;23:1047-52.
47. Thalheimer U, Mela M, Patch D, et al. Prevention of variceal rebleeding. Lancet 2003;361:2244-5.
48. Garcia-Pagan JC, Feu F, Bosch J, et al. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991;114:869-73.
49. Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology 2000;31:1239-45.
50. Patti R, D'Amico G, Pasta L, et al. Isosorbide mononitrate (IMN) with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis. A double-blind placebo-controlled randomised trial. J Hepatol 1999;30(suppl 1):81A.